Background: FTD/TPI has demonstrated significantly overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies. Nevertheless, data regarding the pt profile that benefits most from this FTD/TPI is scarce. Some reports have shown optimal benefit for pts with low tumor burden indolent disease, ECOG PS 0-1, and no liver metastasis. Methods: We conducted a retrospective, multicenter, observational study of pts treated with FTD/TPI at eight hospitals from the Galician Research Group on Digestive Tumours (GITuD). Data were analyzed for a correlation between prognostic characteristics (good prognostic characteristics (GPC) vs. poor prognostic characteristics (PPC)), clinicopathological characteristics and survival. The GPC group was composed of pts who have one or two metastatic sites and time from diagnosis of 1st metastases to treatment ≥ 18 months. Results: Between January 1, 2017 and August 20, 2018, 160 pts were included in the study, of which 85 pts (53.1%) were classified as PPC and 75 pts (46.9%), as GPC. Pts with PPC were associated with younger age (60.5 vs. 63.7 years, p=0.034), higher presence of liver metastases (83.5% vs. 60%, p=0.001) and lower incidence of primary tumor resection (34.1% vs. 17.3%, p=0.019), without differences in ECOG PS, RAS mutation, tumor stage at diagnosis, lung metastases and sidedness. In the whole population of pts median OS and PFS were 7.63 months and 2.75 months, respectively. However, in the GPC and PPC groups mPFS were 2.64 vs. 2.33 months, respectively (p=0.311). Also, median OS was 8.23 months for GPC and 6.75 months for PPC, respectively. Interestingly,the mOS reached 10.5 months in those patients in the GPC group without liver metastasis. OS according ECOG PS 0/1/2 were 10.9 vs. 7.8 vs. 4.4 months, respectively (p=0.004) in the GPC group of pts. Conclusions: We have identified a subgroup of pts who most benefit from FTD/TPI, characterized by ECOG PS 0, low tumor burden, indolent disease and no liver metastasis.